Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 28;16(12):1393-1399.
doi: 10.1039/D4PY01166J. Epub 2025 Feb 21.

Acid-cleavable poly(oxazoline) surfactants

Affiliations

Acid-cleavable poly(oxazoline) surfactants

Joseph A Garcia et al. Polym Chem. .

Abstract

The acidic tumor microenvironment and late endosomes present a promising target for stimuli-responsive nanotherapeutics. Acid-cleavable surfactants, particularly those with hydrazone linkages, offer enhanced stability outside the cell while enabling efficient intracellular payload release. Their acid-triggered cleavage and cationic byproducts facilitate endosomal escape, making them attractive for cancer nanomedicine. Herein, we report the synthesis of a new hydrazone-linked poly(oxazoline)-based diblock copolymer surfactant. This surfactant cleaves in a pH-dependent manner going from pH 7.4 down to pH 5.0, where after 21 h, 80% ± 3% of the hydrazone-linked polymer remained at pH 7.4 compared to 17% ± 2% at pH 5.0. We then demonstrate the ability of nanoemulsion encapsulated payloads to partition into cell membrane mimics only after cleavage of the surfactant. Through this system, we were able to increase the amount of payload release from 26% to 47% over 42 hours through pH changes. In all, this work demonstrates a viable route to create POx-based nanomaterials with controlled release capabilities in biologically relevant conditions and is a promising platform for advancing the endosomal escape and cancer targeting of nanomaterials.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest There are no conflicts to declare.

References

    1. Kou L, Bhutia YD, Yao Q, He Z, Sun J and Ganapathy V, Front. Pharmacol, 2018, 9, DOI: 10.3389/fphar.2018.00027. - DOI
    1. Thapa RK and Kim JO, J. Pharm. Invest, 2023, 53, 19–33.
    1. Weissig V, Pettinger TK and Murdock N, Int. J. Nanomed, 2014, 9, 4357–4373.
    1. Kronberg B, Curr. Opin. Colloid Interface Sci, 2016, 22, 14–22.
    1. Barhoumi A, Liu Q and Kohane DS, J. Controlled Release, 2015, 219, 31–42.